ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0364

Efficacy of BIIB059 on Joint and Skin Manifestations in Participants with Systemic Lupus Erythematosus (SLE): Exploratory Analyses of the Phase 2, Randomized, Double-Blind, Placebo-Controlled LILAC Study (Part A)
Abstract Number: 0365

Improvements in Skin Manifestations with BIIB059 Measured by CLASI in Participants with Cutaneous Lupus Erythematosus (CLE): Exploratory Analyses of the Phase 2, Randomized, Double-Blind, Placebo-Controlled LILAC Study (Part B)
Abstract Number: 0366

Phase II Trial of Enpatoran in Patients Hospitalized with COVID-19 Pneumonia
Abstract Number: 0367

Comparative Risk of COVID-19 Among Patients with Systemic Lupus Erythematosus According to Immunosuppressant Use
Abstract Number: 0368

Which Are the Best Therapeutic Strategies for Systemic Lupus Erythematosus Severe Thrombocytopenia? A Ten Year Analysis
Abstract Number: 0369

The Longitudinal Measurement Properties and Clinical Application of the PROMIS Fatigue 13a and 10a in Lupus
Abstract Number: 0370

Preliminary Findings from a Randomized Clinical Trial Show a Remotely Delivered Psychological Intervention May Be Beneficial to Youth with Childhood-Onset Lupus
Abstract Number: 0371

A Phase 2, Double-blind, Randomized, Placebo-Controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101/Lenabasum in Systemic Lupus Erythematosus, an Autoimmunity Centers of Excellence Study (ALE09)
Abstract Number: 0372

Incidence and Risk of Overall Infections in Patients with Ankylosing Spondylitis Receiving Biologic Therapies: A Real-world Prospective Observational Study Using KOBIO Registry
Abstract Number: 0373

Factors Associated with Adverse Outcomes in Uveitis Related to Spondylarthritis (SpA-U)- Development of a Prognostic Outcome Score in Patients with SpA-U
Abstract Number: 0374

The BASDAI Index During Pregnancy
Abstract Number: 0375

The Presence of Heel Enthesitis on Physical Exploration Is Associated with Poorer Outcomes After 2 Years of Follow-up in Patients with Radiographic Axial Spondyloarthritis
Abstract Number: 0376

The Socioeconomic Profile of Patients with Radiographic Axial Spondyloarthritis Is Associated with the Severity of the Disease and with the Permanent Disability. a Cluster Analysis in a National Spanish Registry
Abstract Number: 0377

Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RESPONDIA and REGISPONSER Studies
Abstract Number: 0378

Prevalence of Axial Spondyloarthritis (axSpA) in Patients Treated for Chronic Back Pain in Chiropractic Clinics

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].